NASDAQ:MBRX
Moleculin Biotech Inc Stock News
$4.76
-0.0200 (-0.418%)
At Close: May 10, 2024
Moleculin Announces Inclusion in the Russell 2000® Index
09:05am, Tuesday, 15'th Jun 2021
HOUSTON, June 15, 2021 /PRNewswire/ -- Moleculin Biotech, Inc. , (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates target
Moleculin Biotech to Start Testing Annamycin in Sarcoma Lung Metastases Patients
11:23am, Tuesday, 25'th May 2021
The FDA has signed off Phase 1b/2 trial for Moleculin Biotech Inc's (NASDAQ: MBRX) Annamycin to treat soft tissue sarcoma lung metastases. Annamycin is the company's next-generation anthracycline t
Moleculin Commences Phase 1b/2 Clinical Trial of Annamycin for the Treatment of Sarcoma Lung Metastases
09:05am, Tuesday, 25'th May 2021
HOUSTON, May 25, 2021 /PRNewswire/ -- Moleculin Biotech, Inc. , (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeti
Moleculin Reports First Quarter 2021 Financial Results and Provides Programs Update
07:35am, Wednesday, 12'th May 2021
HOUSTON, May 12, 2021 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting h
Moleculin Biotech to Present at the Q2 Virtual Investor Summit
08:05am, Tuesday, 11'th May 2021
HOUSTON, May 11, 2021 /PRNewswire/ -- Moleculin Biotech, Inc. , (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeti
WPD Pharmaceuticals to Receive $6.7 Million Grant for Development of Annamycin Drug Candidate
07:30am, Tuesday, 11'th May 2021
VANCOUVER, British Columbia, May 11, 2021 (GLOBE NEWSWIRE) -- WPD Pharmaceuticals Inc. (CSE: WBIO)(FSE: 8SV1) (the “Company” or “WPD”) a clinical-stage pharmaceutical company, is pleased to an
MBRX Stock: Over 10% Pre-Market Explanation
08:07am, Wednesday, 14'th Apr 2021
The stock price of Moleculin Biotech Inc (NASDAQ: MBRX) increased by over 10% pre-market. This is why it happened.
Moleculin Awarded New Rare Pediatric Disease Designation from U.S. FDA for WP1066 for the Treatment of Ependymoma
07:35am, Wednesday, 14'th Apr 2021
HOUSTON, April 14, 2021 /PRNewswire/ -- Moleculin Biotech, Inc. , (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates tar
MBRX Stock Price Increased Over 20% Pre-Market: Why It Happened
08:14am, Tuesday, 30'th Mar 2021
The stock price of Moleculin Biotech, Inc., (Nasdaq: MBRX) fell by over 20% pre-market. This is why it happened.
Moleculin Receives FDA Approval of Fast Track Designation for Annamycin in the Treatment of Sarcoma Lung Metastases
07:30am, Tuesday, 30'th Mar 2021
HOUSTON, March 30, 2021 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting
Moleculin Biotech, Inc. Reports Financial Results for the Year Ended December 31, 2020
07:30am, Wednesday, 24'th Mar 2021
HOUSTON, March 24, 2021 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targetin
HOUSTON, Feb. 8, 2021 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting hi
MBRX Stock Price Falls Over 16% Pre-Market: Why It Happened
08:01am, Wednesday, 03'rd Feb 2021
The stock price of Moleculin Biotech Inc (NASDAQ: MBRX) fell over 16% pre-market as of 7:55 AM ET today. This is why it happened.
Moleculin Announces Proposed Underwritten Public Offering
04:22pm, Tuesday, 02'nd Feb 2021
HOUSTON, Feb. 2, 2021 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targetin
MBRX Stock Price Increases Over 60% Pre-Market: Why It Happened
09:16am, Tuesday, 02'nd Feb 2021
The stock price of Moleculin Biotech Inc (NASDAQ: MBRX) is trading at over 60% pre-market as of 9:12 AM ET. This is why it happened.
